Catalyst Dossier · compiled by CeliA 🧫

HEALTHCARE SERVICES GROUP INC (HCSG)

Services-Nursing & Personal Care Facilities · market cap $1.6B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-22

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Healthcare Services Group Inc (HCSG) is a services-sector company with ~35,300 employees operating in nursing and personal care facilities, generating roughly $1.84B in annual revenue as of fiscal 2025. Despite being classified as a healthcare services operator, the company carries an unusual pipeline including Phase 3 assets (marimastat for lung cancer, a tinea pedis treatment, and a bacterial vaginosis product) alongside a Phase 2 seborrheic dermatitis candidate — assets that appear incongruent with its core business description. The stock trades at ~$24.56 with a market cap of ~$1.69B, and a near-term earnings catalyst is scheduled for July 22, 2026.

The catalyst path

2026-07-22Earningsimp 5/10

Pipeline

Asset	Phase	Indication
marimastat	Phase 3	Lung Cancer
33525	Phase 3	Tinea Pedis
Product 55394	Phase 3	Bacterial Vaginosis
Test Product 49778	Phase 2	Seborrheic Dermatitis

Price & technical context

3-month

+35.4%

6-month

+26.4%

12-month

+67.1%

52-wk range

$12.69–$25.11

vs 50-day MA

+15.4%

vs 200-day MA

+29.3%

Realized vol

43.8%

Max drawdown

-27.4%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HCSG (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.